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Data about patients’ self-perceived severity, symptoma-
tology, and demographic variables such as education and
income were collected.
RESULTS: Results were analyzed with ordinary least
square regression (OLS). The dependent variable is maxi-
mum willingness to pay (WTP), which is defined as the
largest dollar value of the “yes, definitely” or “yes, prob-
ably” response to the bids. Independent variables in-
cluded income, education, self-perceived severity, symp-
tom bothersomeness, number of medical appointments
for their condition in the past year, and number of years
having the condition.
CONCLUSION: The OLS analysis produced a higher ex-
pected WTP for cure than for improvement. The R-square
and F statistics for each model showed that the variables
in the model strongly explain the variation of WTP at a
significant level. The regression results showed that edu-
cation and number of medical appointments in the past
year had a positive impact on willingness to pay for im-
provement, while education and self-perceived severity
demonstrated a positive impact on WTP for cure.
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Long-term maintenance therapies with proton pump inhib-
itor (PPI), H2 receptor-antagonist (H2RA), or prokinetic
agents are often utilized in patients with symptoms of gas-
troesophageal reflux disease (GERD) or erosive esophagitis.
Maintenance therapy can be short-term symptomatic drug
treatment repeated when symptoms reoccur (intermittent)
or long-term continuous treatment (continuous).
OBJECTIVE: To assess which maintenance treatment re-
sults in the most asymptomatic patients, and for continu-
ous treatment, to assess if the dose should be reduced
(step-down therapy) or the patient switched to another
drug.
METHODS: A decision tree analytic model with a 1-year
time frame comparing clinical outcomes of maintenance
drug treatment options with omeprazole, ranitidine, or
cisapride was used. Healing rates used in the model were
determined by meta-analysis of randomized clinical stud-
ies. The decision tree was constructed based on published
treatment algorithms.
RESULTS: For continuous treatment: at 4 months, 94%
of patients taking omeprazole 20 mg daily were asymp-
tomatic vs 77% for ranitidine 300 mg daily. Stepping
down from omeprazole 20 mg to 10 mg resulted in 91%
asymptomatic, and switching to ranitidine 300 mg daily
resulted in 77% of patients asymptomatic; at 12 months,
99% of patients were asymptomatic for all continuous
treatment options. However, of these, 63% had no treat-
ment failures throughout the year for omeprazole 20 mg,
versus 51% for patients stepped down to omeprazole 10
mg daily, versus 32% for patients switched to ranitidine
300 mg daily, and versus 38% for patients taking raniti-
dine 300 mg daily initially. For intermittent treatment: at
12 months, 79%, 76%, and 80% of patients were asymp-
tomatic for omeprazole 20 mg, ranitidine 300 mg, and
cisapride 40 mg daily, respectively. 
CONCLUSIONS: Continuous maintenance treatment
options resulted in more patients asymptomatic than in-
termittent treatment options. Continuous treatment with
PPI resulted in more patients asymptomatic with fewer
treatment failures throughout the year vs H2RA, step-
down, or switch therapy.
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In the UK, certain anti-ulcer agents are used for prophy-
laxis against non-steroidal anti-inflammatory drug (NSAID)
toxicity.
OBJECTIVE: The objective of this study was to compare
the incidence of hospitalizations for gastrointestinal events
during exposure to these ulcer-healing drugs coprescribed
with NSAIDs.
METHODS: This was a population-based, observational,
record linkage study that included 427,786 patients regis-
tered with general practitioners in Tayside, Scotland be-
tween 1989 and 1994. Redeemed prescriptions for NSAIDs
and anti-ulcer drugs, and hospital discharge diagnoses of
patients to whom they were given, were obtained.
RESULTS: The risks of hospitalization for a gastrointes-
tinal event during concurrent exposure to NSAIDs and ei-
ther misoprostol or proton-pump inhibitors, adjusted for
recorded risk factors, were no greater than during expo-
sure to NSAIDs alone in patients with and without a
prior history of such events. By contrast, adjusted event
rates were twice as high during combined exposure to H2
receptor antagonist and NSAID compared with NSAIDs
alone in patients with a prior history (p  0.001), and
20% higher in patients without (p  0.001). Risks of
hospitalizations for gastroduodenal ulcers, erosions, gas-
tritis, and duodenitis during exposure to misoprostol were
23% less than those during exposure to H2 receptor an-
tagonists (p  0.001). No such difference was found with
proton-pump inhibitors. Despite the apparent greater ef-
ficacy of misoprostol and proton-pump inhibitors relative
to H2 receptor antagonists in patients with a prior his-
tory, their use was less common in these high-risk pa-
tients. 
CONCLUSIONS: The observed preferential use of H2
